Gary Nachman
Stock Analyst at Canaccord Genuity
(2.12)
# 3,026
Out of 4,405 analysts
468
Total ratings
45.4%
Success rate
0.3%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintained: Buy | $110 | $73.28 | +50.12% | 30 | Jun 5, 2026 | |
| SRRK Scholar Rock Holding | Reiterated: Buy | $62 | $44.18 | +40.33% | 13 | Jun 2, 2026 | |
| ACHV Achieve Life Sciences | Rated: Buy | $13 | $5.52 | +135.51% | 7 | May 21, 2026 | |
| ADMA ADMA Biologics | Maintained: Buy | $21 → $18 | $8.21 | +119.24% | 7 | May 5, 2026 | |
| AMGN Amgen | Maintained: Hold | $366 | $355.20 | +3.04% | 3 | May 1, 2026 | |
| ABBV AbbVie | Reiterated: Buy | $262 → $265 | $227.73 | +16.37% | 42 | Apr 30, 2026 | |
| PCRX Pacira BioSciences | Maintained: Hold | n/a | $22.99 | - | 48 | Oct 6, 2025 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | $16.74 | $8.45 | +98.05% | 7 | Oct 2, 2025 | |
| VERU Veru Inc. | Maintained: Buy | $3 → $20 | $3.00 | +566.67% | 2 | Aug 13, 2025 | |
| INMB INmune Bio | Reiterated: Hold | n/a | $1.24 | - | 5 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 → $40 | $6.77 | +490.84% | 2 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $86 | $81.68 | +5.29% | 4 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 | $4.17 | +67.87% | 18 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $230.56 | n/a | 48 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $22 | $15.08 | n/a | 2 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $298 | $282.85 | n/a | 23 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $4 | $73.44 | n/a | 7 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $200 → $100 | $0.0003 | n/a | 8 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $4 | $9.60 | n/a | 22 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $4 | $16.20 | n/a | 19 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $30 | $10.37 | n/a | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $83 → $78 | $14.45 | n/a | 5 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $14 | $16.48 | n/a | 17 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $11.16 → $13.95 | $7.09 | n/a | 42 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $40 → $32 | $5.24 | n/a | 11 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $10 | $34.63 | n/a | 7 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $3 | $32.85 | n/a | 11 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 → $35 | $0.00001 | n/a | 10 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 → $25 | $4.62 | n/a | 6 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $180 | $2.78 | n/a | 3 | Aug 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $13 → $12 | $14.21 | n/a | 5 | May 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $21 | $20.03 | n/a | 14 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 → $3 | $0.0001 | n/a | 5 | Sep 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $80 | $43.93 | n/a | 1 | Sep 14, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $138 | $88.57 | n/a | 3 | Apr 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $9.5 → $14 | $3.65 | n/a | 2 | Mar 21, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6.8 | $15.24 | n/a | 2 | Oct 9, 2013 |
Ionis Pharmaceuticals
Jun 5, 2026
Maintained: Buy
Price Target: $110
Current: $73.28
Upside: +50.12%
Scholar Rock Holding
Jun 2, 2026
Reiterated: Buy
Price Target: $62
Current: $44.18
Upside: +40.33%
Achieve Life Sciences
May 21, 2026
Rated: Buy
Price Target: $13
Current: $5.52
Upside: +135.51%
ADMA Biologics
May 5, 2026
Maintained: Buy
Price Target: $21 → $18
Current: $8.21
Upside: +119.24%
Amgen
May 1, 2026
Maintained: Hold
Price Target: $366
Current: $355.20
Upside: +3.04%
AbbVie
Apr 30, 2026
Reiterated: Buy
Price Target: $262 → $265
Current: $227.73
Upside: +16.37%
Pacira BioSciences
Oct 6, 2025
Maintained: Hold
Price Target: n/a
Current: $22.99
Upside: -
Eupraxia Pharmaceuticals Inc.
Oct 2, 2025
Maintained: Buy
Price Target: $16.74
Current: $8.45
Upside: +98.05%
Veru Inc.
Aug 13, 2025
Maintained: Buy
Price Target: $3 → $20
Current: $3.00
Upside: +566.67%
INmune Bio
Aug 4, 2025
Reiterated: Hold
Price Target: n/a
Current: $1.24
Upside: -
Jul 31, 2025
Maintained: Buy
Price Target: $37 → $40
Current: $6.77
Upside: +490.84%
Jun 20, 2025
Reiterated: Buy
Price Target: $86
Current: $81.68
Upside: +5.29%
Jun 17, 2025
Maintained: Buy
Price Target: $7
Current: $4.17
Upside: +67.87%
Jun 11, 2025
Maintained: Hold
Price Target: n/a
Current: $230.56
Upside: n/a
Feb 20, 2025
Maintained: Buy
Price Target: $19 → $22
Current: $15.08
Upside: n/a
Jan 15, 2025
Reiterated: Buy
Price Target: $298
Current: $282.85
Upside: n/a
Aug 19, 2024
Maintained: Buy
Price Target: $7 → $4
Current: $73.44
Upside: n/a
Mar 16, 2023
Rated: Buy
Price Target: $200 → $100
Current: $0.0003
Upside: n/a
Mar 8, 2023
Maintained: Buy
Price Target: $5 → $4
Current: $9.60
Upside: n/a
Mar 2, 2023
Rated: Hold
Price Target: $4
Current: $16.20
Upside: n/a
Mar 1, 2023
Maintained: Buy
Price Target: $35 → $30
Current: $10.37
Upside: n/a
Mar 1, 2023
Maintained: Buy
Price Target: $83 → $78
Current: $14.45
Upside: n/a
Feb 27, 2023
Rated: Hold
Price Target: $14
Current: $16.48
Upside: n/a
Feb 24, 2023
Maintained: Hold
Price Target: $11.16 → $13.95
Current: $7.09
Upside: n/a
Feb 22, 2023
Rated: Buy
Price Target: $40 → $32
Current: $5.24
Upside: n/a
Feb 8, 2023
Rated: Hold
Price Target: $10
Current: $34.63
Upside: n/a
Jan 9, 2023
Rated: Buy
Price Target: $3
Current: $32.85
Upside: n/a
Nov 10, 2022
Maintained: Buy
Price Target: $60 → $35
Current: $0.00001
Upside: n/a
Aug 11, 2022
Reiterated: Buy
Price Target: $27 → $25
Current: $4.62
Upside: n/a
Aug 2, 2021
Maintained: Buy
Price Target: $180
Current: $2.78
Upside: n/a
May 14, 2021
Rated: Buy
Price Target: $13 → $12
Current: $14.21
Upside: n/a
May 11, 2020
Maintained: Hold
Price Target: $21
Current: $20.03
Upside: n/a
Sep 5, 2019
Maintained: Buy
Price Target: $9 → $3
Current: $0.0001
Upside: n/a
Sep 14, 2017
Maintained: Buy
Price Target: $80
Current: $43.93
Upside: n/a
Apr 27, 2017
Reiterated: Buy
Price Target: $138
Current: $88.57
Upside: n/a
Mar 21, 2016
Initiated Coverage: Hold
Price Target: $9.5 → $14
Current: $3.65
Upside: n/a
Oct 9, 2013
Maintained: Hold
Price Target: $6.8
Current: $15.24
Upside: n/a